A Transcriptomic Biomarker Predicting Linezolid-Associated Neuropathy During Treatment of Drug-Resistant Tuberculosis
Article Sidebar
Main Article Content
Abstract
Background: Neuropathic adverse events occur frequently in linezolid-containing regimens, some of which remain irreversible after drug discontinuation.
Objective: We aimed to identify and validate a host RNA-based biomarker that can predict linezolid-associated neuropathy before multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) treatment initiation and to identify genes and pathways that are associated with linezolid-associated neuropathy.
Methods: Adult patients initiating MDR/RR-TB treatment including linezolid were prospectively enrolled in 3 independent cohorts in Germany. Clinical data and whole blood RNA for transcriptomic analysis were collected. The primary outcome was linezolid-associated optic and/or peripheral neuropathy. A random forest algorithm was used for biomarker identification. The biomarker was validated in an additional fourth cohort of patients with MDR/RR-TB from Romania.
Results: A total of 52 patients from the 3 identification cohorts received linezolid treatment. Of those, 24 (46.2%) developed peripheral and/or optic neuropathies during linezolid treatment. The majority (59.3%) of the episodes were of moderate (grade 2) severity. In total, the expression of 1,479 genes differed significantly at baseline of treatment. Suprabasin (SBSN) was identified as a potential biomarker to predict linezolid-associated neuropathy. In the validation cohort, 10 of 42 (23.8%) patients developed grade ≥3 neuropathies. The area under the curve for the biomarker algorithm prediction of grade ≥3 neuropathies was 0.63 (poor; 95% confidence interval: 0.42 – 0.84).
Conclusions: We identified and preliminarily validated a potential clinical biomarker to predict linezolid-associated neuropathies before the initiation of MDR/RR-TB therapy. Larger studies of the SBSN biomarker in more diverse populations are warranted.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Pathogens and Immunity abides by Creative Commons BY 4.0:
http://creativecommons.org/licenses/by/4.0/
This license lets others distribute, remix, tweak, and build upon your work for any lawful purpose, even commercially, as long as they credit you for the original creation. This is the most accommodating of licenses offered. Recommended for maximum dissemination and use of licensed materials. The authors maintain copyright of their materal.
*Due to a template error on our pdfs, articles published from May 20, 2016 to June 24, 2022 incorrectly state the copyright is held by Pathogens and Immunity. Copyright of all articles is held by the authors of each article as noted in the above copyright policy.
References
1. World Health Organization. Global tuberculosis report 2023. Geneva: World Health Organization; 2023.
2. Lange C, Dheda K, Chesov D, Mandalakas AM, Udwadia Z, Horsburgh CR, Jr. Management of drug-resistant tuberculosis. Lancet. 2019;394(10202):953-66. doi: 10.1016/S0140-6736(19)31882-3. PubMed PMID: 31526739.
3. World Health Organization. WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-resistant tuberculosis treatment. 2022 update ed. Geneva: World Health Organization; 2022.
4. Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, Mendel CM, Egizi E, Moreira J, Timm J, McHugh TD, Wills GH, Bateson A, Hunt R, Van Niekerk C, Li M, Olugbosi M, Spigelman M, Nix TBTT. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. N Engl J Med. 2020;382(10):893-902. doi: 10.1056/NEJMoa1901814. PubMed PMID: 32130813; PMCID: PMC6955640.
5. Lan Z, Ahmad N, Baghaei P, Barkane L, Benedetti A, Brode SK, Brust JCM, Campbell JR, Chang VWL, Falzon D, Guglielmetti L, Isaakidis P, Kempker RR, Kipiani M, Kuksa L, Lange C, Laniado-Laborin R, Nahid P, Rodrigues D, Singla R, Udwadia ZF, Menzies D, Collaborative Group for the Meta-Analysis of Individual Patient Data in MDRTBt. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir Med. 2020;8(4):383-94. doi: 10.1016/S2213-2600(20)30047-3. PubMed PMID: 32192585; PMCID: PMC7384398.
6. Eimer J, Frechet-Jachym M, Le Du D, Caumes E, El-Helali N, Marigot-Outtandy D, Mechai F, Peytavin G, Pourcher V, Rioux C, Yazdanpanah Y, Robert J, Guglielmetti L, group L. Association Between Increased Linezolid Plasma Concentrations and the Development of Severe Toxicity in Multidrug-Resistant Tuberculosis Treatment. Clin Infect Dis. 2023;76(3):e947-e56. doi: 10.1093/cid/ciac485. PubMed PMID: 35717636.
7. Conradie F, Bagdasaryan TR, Borisov S, Howell P, Mikiashvili L, Ngubane N, Samoilova A, Skornykova S, Tudor E, Variava E, Yablonskiy P, Everitt D, Wills GH, Sun E, Olugbosi M, Egizi E, Li M, Holsta A, Timm J, Bateson A, Crook AM, Fabiane SM, Hunt R, McHugh TD, Tweed CD, Foraida S, Mendel CM, Spigelman M, ZeNix Trial T. Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis. N Engl J Med. 2022;387(9):810-23. doi: 10.1056/NEJMoa2119430. PubMed PMID: 36053506; PMCID: PMC9490302.
8. Nyang’wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, Solodovnikova V, Liverko I, Moodliar R, Dodd M, Ngubane N, Rassool M, McHugh TD, Spigelman M, Moore DAJ, Ritmeijer K, du Cros P, Fielding K, Collaborators T-PS. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis. N Engl J Med. 2022;387(25):2331-43. doi: 10.1056/NEJMoa2117166. PubMed PMID: 36546625.
9. Yuan Y, Li J, Chen Y, Cai Q, Xu Y, Lin L, Lang Y, Guo S, Zhang R, Cai X. Mechanism underlying linezolid-induced peripheral neuropathy in multidrug-resistant tuberculosis. Front Pharmacol. 2022;13:946058. doi: 10.3389/fphar.2022.946058. PubMed PMID: 36160387; PMCID: PMC9500448.
10. De Vriese AS, Coster RV, Smet J, Seneca S, Lovering A, Van Haute LL, Vanopdenbosch LJ, Martin JJ, Groote CC, Vandecasteele S, Boelaert JR. Linezolid-induced inhibition of mitochondrial protein synthesis. Clin Infect Dis. 2006;42(8):1111-7. doi: 10.1086/501356. PubMed PMID: 16575728.
11. Song T, Lee M, Jeon HS, Park Y, Dodd LE, Dartois V, Follman D, Wang J, Cai Y, Goldfeder LC, Olivier KN, Xie Y, Via LE, Cho SN, Barry CE, 3rd, Chen RY. Linezolid Trough Concentrations Correlate with Mitochondrial Toxicity-Related Adverse Events in the Treatment of Chronic Extensively Drug-Resistant Tuberculosis. EBioMedicine. 2015;2(11):1627-33. doi: 10.1016/j.ebiom.2015.09.051. PubMed PMID: 26870788; PMCID: PMC4740314.
12. Lange C, Aarnoutse RE, Alffenaar JWC, Bothamley G, Brinkmann F, Costa J, Chesov D, van Crevel R, Dedicoat M, Dominguez J, Duarte R, Grobbel HP, Gunther G, Guglielmetti L, Heyckendorf J, Kay AW, Kirakosyan O, Kirk O, Koczulla RA, Kudriashov GG, Kuksa L, van Leth F, Magis-Escurra C, Mandalakas AM, Molina-Moya B, Peloquin CA, Reimann M, Rumetshofer R, Schaaf HS, Schon T, Tiberi S, Valda J, Yablonskii PK, Dheda K. Management of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2019;23(6):645-62. doi: 10.5588/ijtld.18.0622. PubMed PMID: 31315696.
13. Zak DE, Penn-Nicholson A, Scriba TJ, Thompson E, Suliman S, Amon LM, Mahomed H, Erasmus M, Whatney W, Hussey GD, Abrahams D, Kafaar F, Hawkridge T, Verver S, Hughes EJ, Ota M, Sutherland J, Howe R, Dockrell HM, Boom WH, Thiel B, Ottenhoff THM, Mayanja-Kizza H, Crampin AC, Downing K, Hatherill M, Valvo J, Shankar S, Parida SK, Kaufmann SHE, Walzl G, Aderem A, Hanekom WA, Acs, groups GCcs. A blood RNA signature for tuberculosis disease risk: a prospective cohort study. Lancet. 2016;387(10035):2312-22. doi: 10.1016/S0140-6736(15)01316-1. PubMed PMID: 27017310; PMCID: PMC5392204.
14. Scriba TJ, Fiore-Gartland A, Penn-Nicholson A, Mulenga H, Kimbung Mbandi S, Borate B, Mendelsohn SC, Hadley K, Hikuam C, Kaskar M, Musvosvi M, Bilek N, Self S, Sumner T, White RG, Erasmus M, Jaxa L, Raphela R, Innes C, Brumskine W, Hiemstra A, Malherbe ST, Hassan-Moosa R, Tameris M, Walzl G, Naidoo K, Churchyard G, Hatherill M, Team C-S. Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial. Lancet Infect Dis. 2021;21(3):354-65. doi: 10.1016/S1473-3099(20)30914-2. PubMed PMID: 33508224; PMCID: PMC7907670.
15. Heyckendorf J, Reimann M, Marwitz S, Lange C, group D-Tcs. Pathogen-free diagnosis of tuberculosis. Lancet Infect Dis. 2021;21(8):1066. doi: 10.1016/S1473-3099(21)00337-6. PubMed PMID: 34331877.
16. Heyckendorf J, Marwitz S, Reimann M, Avsar K, DiNardo AR, Gunther G, Hoelscher M, Ibraim E, Kalsdorf B, Kaufmann SHE, Kontsevaya I, van Leth F, Mandalakas AM, Maurer FP, Muller M, Nitschkowski D, Olaru ID, Popa C, Rachow A, Rolling T, Rybniker J, Salzer HJF, Sanchez-Carballo P, Schuhmann M, Schaub D, Spinu V, Suarez I, Terhalle E, Unnewehr M, Weiner J, 3rd, Goldmann T, Lange C. Prediction of anti-tuberculosis treatment duration based on a 22-gene transcriptomic model. Eur Respir J. 2021;58(3). doi: 10.1183/13993003.03492-2020. PubMed PMID: 33574078.
17. Schaberg T, Bauer T, Castell S, Dalhoff K, Detjen A, Diel R, Greinert U, Hauer B, Lange C, Magdorf K, Loddenkemper R. [Recommendations for therapy, chemoprevention and chemoprophylaxis of tuberculosis in adults and children. German Central Committee against Tuberculosis (DZK), German Respiratory Society (DGP)]. Pneumologie. 2012;66(3):133-71. doi: 10.1055/s-0031-1291619. PubMed PMID: 22328186.
18. Schaberg T, Bauer T, Brinkmann F, Diel R, Feiterna-Sperling C, Haas W, Hartmann P, Hauer B, Heyckendorf J, Lange C, Nienhaus A, Otto-Knapp R, Priwitzer M, Richter E, Rumetshofer R, Schenkel K, Schoch OD, Schonfeld N, Stahlmann R. [Tuberculosis Guideline for Adults - Guideline for Diagnosis and Treatment of Tuberculosis including LTBI Testing and Treatment of the German Central Committee (DZK) and the German Respiratory Society (DGP)]. Pneumologie. 2017;71(6):325-97. doi: 10.1055/s-0043-105954. PubMed PMID: 28651293.
19. World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization; 2014.
20. World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis. 2016 update ed. Geneva: World Health Organization; 2016.
21. World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2019.
22. World Health Organization. WHO operational handbook on tuberculosis: module 4: treatment: drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2020.
23. endTB Consortium. TB Severity Grading Scale Version 5. 2016.
24. Park GT, Lim SE, Jang SI, Morasso MI. Suprabasin, a novel epidermal differentiation marker and potential cornified envelope precursor. J Biol Chem. 2002;277(47):45195-202. doi: 10.1074/jbc.M205380200. PubMed PMID: 12228223; PMCID: PMC1283087.
25. Zhu J, Wu G, Li Q, Gong H, Song J, Cao L, Wu S, Song L, Jiang L. Overexpression of Suprabasin is Associated with Proliferation and Tumorigenicity of Esophageal Squamous Cell Carcinoma. Sci Rep. 2016;6:21549. doi: 10.1038/srep21549. PubMed PMID: 26899563; PMCID: PMC4761926.
26. Shao C, Tan M, Bishop JA, Liu J, Bai W, Gaykalova DA, Ogawa T, Vikani AR, Agrawal Y, Li RJ, Kim MS, Westra WH, Sidransky D, Califano JA, Ha PK. Suprabasin is hypomethylated and associated with metastasis in salivary adenoid cystic carcinoma. PLoS One. 2012;7(11):e48582. doi: 10.1371/journal.pone.0048582. PubMed PMID: 23144906; PMCID: PMC3492451.
27. Ichinose K, Ohyama K, Furukawa K, Higuchi O, Mukaino A, Satoh K, Nakane S, Shimizu T, Umeda M, Fukui S, Nishino A, Nakajima H, Koga T, Kawashiri SY, Iwamoto N, Tamai M, Nakamura H, Origuchi T, Yoshida M, Kuroda N, Kawakami A. Novel anti-suprabasin antibodies may contribute to the pathogenesis of neuropsychiatric systemic lupus erythematosus. Clin Immunol. 2018;193:123-30. doi: 10.1016/j.clim.2017.11.006. PubMed PMID: 29162406.
28. Aoshima M, Phadungsaksawasdi P, Nakazawa S, Iwasaki M, Sakabe JI, Umayahara T, Yatagai T, Ikeya S, Shimauchi T, Tokura Y. Decreased expression of suprabasin induces aberrant differentiation and apoptosis of epidermal keratinocytes: Possible role for atopic dermatitis. J Dermatol Sci. 2019;95(3):107-12. doi: 10.1016/j.jdermsci.2019.07.009. PubMed PMID: 31399284.
29. Sjostedt E, Zhong W, Fagerberg L, Karlsson M, Mitsios N, Adori C, Oksvold P, Edfors F, Limiszewska A, Hikmet F, Huang J, Du Y, Lin L, Dong Z, Yang L, Liu X, Jiang H, Xu X, Wang J, Yang H, Bolund L, Mardinoglu A, Zhang C, von Feilitzen K, Lindskog C, Ponten F, Luo Y, Hokfelt T, Uhlen M, Mulder J. An atlas of the protein-coding genes in the human, pig, and mouse brain. Science. 2020;367(6482). doi: 10.1126/science.aay5947. PubMed PMID: 32139519.
30. Kim SW, Kim KT. Expression of Genes Involved in Axon Guidance: How Much Have We Learned? Int J Mol Sci. 2020;21(10). doi: 10.3390/ijms21103566. PubMed PMID: 32443632; PMCID: PMC7278939.
31. Pribyl M, Hodny Z, Kubikova I. Suprabasin-A Review. Genes (Basel). 2021;12(1). doi: 10.3390/genes12010108. PubMed PMID: 33477529; PMCID: PMC7831088.
32. Chen H, Chen X, Zhang Z, Bao W, Gao Z, Li D, Xie X, Zhou P, Yang C, Zhou Z, Pan J, Kuang X, Tang R, Feng Z, Zhou L, Zhu D, Yang J, Wang L, Huang H, Tang D, Liu J, Jiang L. Extracellular vesicles-transferred SBSN drives glioma aggressiveness by activating NF-kappaB via ANXA1-dependent ubiquitination of NEMO. Oncogene. 2022;41(49):5253-65. doi: 10.1038/s41388-022-02520-6. PubMed PMID: 36316443.
33. Uehara T, Kondo C, Yamate J, Torii M, Maruyama T. A toxicogenomic approach for identifying biomarkers for myelosuppressive anemia in rats. Toxicology. 2011;282(3):139-45. doi: 10.1016/j.tox.2011.01.027. PubMed PMID: 21296123.
34. Jaspard M, Butel N, El Helali N, Marigot-Outtandy D, Guillot H, Peytavin G, Veziris N, Bodaghi B, Flandre P, Petitjean G, Caumes E, Pourcher V. Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France. Emerg Infect Dis. 2020;26(8):1792-800. doi: 10.3201/eid2608.191499. PubMed PMID: 32687026; PMCID: PMC7392460.
35. Zhang P, Li W, Liu M, Zhan S, Zhang H, Deng G, Chen X. Linezolid-Associated Neuropathy in Patients with MDR/XDR Tuberculosis in Shenzhen, China. Infect Drug Resist. 2022;15:2617-24. doi: 10.2147/IDR.S365371. PubMed PMID: 35634579; PMCID: PMC9139335.
36. Head KA. Peripheral neuropathy: pathogenic mechanisms and alternative therapies. Altern Med Rev. 2006;11(4):294-329. PubMed PMID: 17176168.
37. Couronne R, Probst P, Boulesteix AL. Random forest versus logistic regression: a large-scale benchmark experiment. BMC Bioinformatics. 2018;19(1):270. doi: 10.1186/s12859-018-2264-5. PubMed PMID: 30016950; PMCID: PMC6050737.